<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa//inpress?rss=yes"><title>The American Journal of Pathology - Articles in Press</title><description>The American Journal of Pathology RSS feed: Articles in Press.    
 The American Journal of Pathology , official journal of the American Society for Investigative Pathology seeks to publish high-quality, 
original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational 
knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. 
High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, 
and immunological approaches in conjunction with morphology.   </description><link>http://www.journals.elsevierhealth.com/periodicals/ajpa//inpress?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:issn>0002-9440</prism:issn><prism:publicationDate>2012-02-20</prism:publicationDate><prism:copyright> © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000363/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000879/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000880/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000892/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000909/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000351/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200034X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000375/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000387/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000430/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000193/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000211/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000223/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000235/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000247/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000259/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000260/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000272/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000284/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000302/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000314/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000326/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000338/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000399/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000405/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000417/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000429/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000156/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200017X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000296/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000181/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200020X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000132/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000363/abstract?rss=yes"><title>Endogenous Erythropoietin Protects Neuroretinal Function in Ischemic Retinopathy - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000363/abstract?rss=yes</link><description>
Because retinal ischemia is a common cause of vision loss, we sought to determine the effects of ischemia on neuroretinal function and survival in murine oxygen-induced retinopathy (OIR) and to define the role of endogenous erythropoietin (EPO) in this model. OIR is a reproducible model of ischemia-induced retinal neovascularization; it is used commonly to develop antiangiogenic strategies. We investigated the effects of ischemia in murine OIR on retinal function and neurodegeneration by electroretinography and detailed morphology. OIR was associated with significant neuroretinal dysfunction, with reduced photopic and scotopic ERG responses and reduced b-wave/a-wave ratios consistent with specific inner-retinal dysfunction. OIR resulted in significantly increased apoptosis and atrophy of the inner retina in areas of ischemia. EPO deficiency in heterozygous Epo-Tag transgenic mice was associated with more profound retinal dysfunction after OIR, indicated by a significantly greater suppression of ERG amplitudes, but had no measurable effect on the extent of retinal ischemia, preretinal neovascularization, or neuroretinal degeneration in OIR. Systemic administration of recombinant EPO protected EPO-deficient mice against this additional suppression, but EPO supplementation in wild-type animals with OIR did not rescue neuroretinal dysfunction or degeneration. Murine OIR offers a valuable model of ischemic neuroretinal dysfunction and degeneration in which to investigate adaptive tissue responses and evaluate novel therapeutic approaches. Endogenous EPO can protect neuroretinal function in ischemic retinopathy.
</description><dc:title>Endogenous Erythropoietin Protects Neuroretinal Function in Ischemic Retinopathy - Uncorrected Proof</dc:title><dc:creator>Freya M. Mowat, Francisco Gonzalez, Ulrich F.O. Luhmann, Clemens Lange, Yanai Duran, Alexander J. Smith, Patrick H. Maxwell, Robin R. Ali, James W.B. Bainbridge</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.033</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-20</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-20</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000879/abstract?rss=yes"><title>Hedgehog-Gli Pathway Activation during Kidney Fibrosis - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000879/abstract?rss=yes</link><description>
The Hedgehog (Hh) signaling pathway regulates tissue patterning during development, including patterning and growth of limbs and face, but whether Hh signaling plays a role in adult kidney remains undefined. In this study, using a panel of hedgehog-reporter mice, we show that the two Hh ligands (Indian hedgehog and sonic hedgehog ligands) are expressed in tubular epithelial cells. We report that the Hh effectors (Gli1 and Gli2) are expressed exclusively in adjacent platelet-derived growth factor receptor-β-positive interstitial pericytes and perivascular fibroblasts, suggesting a paracrine signaling loop. In two models of renal fibrosis, Indian Hh ligand was upregulated with a dramatic activation of downstream Gli effector expression. Hh-responsive Gli1-positive interstitial cells underwent 11-fold proliferative expansion during fibrosis, and both Gli1- and Gli2-positive cells differentiated into α-smooth muscle actin-positive myofibroblasts. In the pericyte-like cell line 10T1/2, hedgehog ligand triggered cell proliferation, suggesting a possible role for this pathway in the regulation of cell cycle progression of myofibroblasts progenitors during the development of renal fibrosis. The hedgehog antagonist IPI-926 abolished Gli1 induction in vivo but did not decrease kidney fibrosis. However, the transcriptional induction of Gli2 was unaffected by IPI-926, suggesting the existence of smoothened-independent Gli activation in this model. This study is the first detailed description of paracrine hedgehog signaling in adult kidney, which indicates a possible role for hedgehog-Gli signaling in fibrotic chronic kidney disease.
</description><dc:title>Hedgehog-Gli Pathway Activation during Kidney Fibrosis - Uncorrected Proof</dc:title><dc:creator>Steven L. Fabian, Radostin R. Penchev, Benoit St. Jacques, Anjali N. Rao, Petra Sipilä, Kip A. West, Andrew P. McMahon, Benjamin D. Humphreys</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.039</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-20</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-20</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000880/abstract?rss=yes"><title>In Vivo Characterization of Mutant Myotilins - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000880/abstract?rss=yes</link><description>
Myofibrillar myopathy (MFM) is a group of disorders that are pathologically defined by the disorganization of the myofibrillar alignment associated with the intracellular accumulation of Z-disk-related proteins. MFM is caused by mutations in genes encoding Z-disk-associated proteins, including myotilin. Although a number of MFM mutations have been identified, it has been difficult to elucidate the precise roles of the mutant proteins. Here, we present a useful method for the characterization of mutant proteins associated with MFM. Expression of mutant myotilins in mouse tibialis anterior muscle by in vivo electroporation recapitulated both the pathological changes and the biochemical characteristics observed in patients with myotilinopathy. In mutant myotilin-expressing muscle fibers, myotilin aggregates and is costained with polyubiquitin, and Z-disk proteins and myofibrillar disorganization were commonly seen. In addition, the expressed S60C mutant myotilin protein displayed marked detergent insolubility in electroporated mouse muscle, similar to that observed in human MFM muscle with the same mutation. Thus, in vivo electroporation can be a useful method for evaluating the pathogenicity of mutations identified in MFM.
</description><dc:title>In Vivo Characterization of Mutant Myotilins - Uncorrected Proof</dc:title><dc:creator>Etsuko Keduka, Yukiko K. Hayashi, Sherine Shalaby, Hiroaki Mitsuhashi, Satoru Noguchi, Ikuya Nonaka, Ichizo Nishino</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.040</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-20</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-20</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000892/abstract?rss=yes"><title>Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000892/abstract?rss=yes</link><description>
Colorectal cancers (CRCs) are classified as having microsatellite instability (MSI) or chromosomal instability (CIN); herein termed microsatellite stable (MSS). MSI colon cancers frequently display a poorly differentiated histology for which the molecular basis is not well understood. In this study, we compared gene expression profiling to histology in both MSI and MSS colon cancers. Gene expression profiling revealed significant down-regulation of the intestinal-specific cytoskeletal protein villin in MSI colon cancer cell lines and tumors, with complete absence in 62% and 17% of MSI cell lines and tumors, respectively. Investigation of 577 CRCs linked loss of villin expression to poorly differentiated histology in MSI and MSS tumors. Furthermore, mislocalization of villin from the membrane was prognostic for poorer outcome in MSS patients. Loss of villin expression was not due to coding sequence mutations, epigenetic inactivation, or promoter mutation. Conversely, in transient transfection assays villin promoter activity reflected endogenous villin expression, suggesting transcriptional control. A screen of gut-specific transcription factors revealed a significant correlation between expression of villin and the homeobox transcription factor (Cdx-1). Cdx-1 overexpression induced villin promoter activity, Cdx-1 knockdown down-regulated endogenous villin expression, and deletion of a key Cdx-binding site within the villin promoter attenuated promoter activity. Loss of Cdx-1 expression was associated with Cdx-1 promoter methylation. These findings demonstrate that loss of villin expression due to Cdx-1 loss is a feature of poorly differentiated CRCs.
</description><dc:title>Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer - Uncorrected Proof</dc:title><dc:creator>Diego Arango, Sheren Al-Obaidi, David S. Williams, Higinio Dopeso, Rocco Mazzolini, Georgia Corner, Do-Sun Byun, Azadeh A. Carr, Carmel Murone, Lars Tögel, Nikolajs Zeps, Lauri A. Aaltonen, Barry Iacopetta, John M. Mariadason</dc:creator><dc:identifier>10.1016/j.ajpath.2012.01.006</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-20</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-20</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000909/abstract?rss=yes"><title>Ferroxidase Hephaestin's Cell: Autonomous Role in the Retinal Pigment Epithelium - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000909/abstract?rss=yes</link><description>
Hephaestin (Heph) is a ferroxidase protein that converts ferrous to ferric iron to facilitate cellular iron export by ferroportin. Many tissues express either Heph or its homologue, ceruloplasmin (Cp), but the retina expresses both. In mice, a combined systemic mutation of Heph and systemic knockout of Cp (Cp−/−, Hephsla/sla) causes retinal iron accumulation and retinal degeneration, with features of human age-related macular degeneration; however, the role of Heph and Cp in the individual retinal cells is unclear. Herein, we used conditional knockout mice to study Heph's role in retinal pigment epithelial (RPE) and photoreceptor cells. Loss of both Heph and Cp from RPE cells alone results in RPE cell iron accumulation and degeneration. We found, however, that RPE iron accumulation in these conditional knockout mice is not as great as in systemic knockout mice. Photoreceptor-specific Heph knockout indicates that the additional iron in the RPE cells does not result from loss of ferroxidases in the photoreceptors, and Cp and Heph play minor roles in photoreceptors. Instead, loss of ferroxidases in other retinal cells causes retinal iron accumulation and transfer of iron to the RPE cells. Cp and Heph are necessary for iron export from the retina but are not essential for iron import into the retina. Thus, our studies, revise how we think about iron import and export from the retina.
</description><dc:title>Ferroxidase Hephaestin's Cell: Autonomous Role in the Retinal Pigment Epithelium - Uncorrected Proof</dc:title><dc:creator>Natalie Wolkow, Delu Song, Ying Song, Sally Chu, Majda Hadziahmetovic, Jennifer C. Lee, Jared Iacovelli, Steven Grieco, Joshua L. Dunaief</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.041</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-20</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-20</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000351/abstract?rss=yes"><title>Role of the Nuclear Receptor Coactivator AIB1/SRC-3 in Angiogenesis and Wound Healing - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000351/abstract?rss=yes</link><description>
The nuclear receptor coactivator amplified in breast cancer 1 (AIB1/SRC-3) has a well-defined role in steroid and growth factor signaling in cancer and normal epithelial cells. Less is known about its function in stromal cells, although AIB1/SRC-3 is up-regulated in tumor stroma and may, thus, contribute to tumor angiogenesis. Herein, we show that AIB1/SRC-3 depletion from cultured endothelial cells reduces their proliferation and motility in response to growth factors and prevents the formation of intact monolayers with tight junctions and of endothelial tubes. In AIB1/SRC-3+/− and −/− mice, the angiogenic responses to subcutaneous Matrigel implants was reduced by two-thirds, and exogenously added fibroblast growth factor (FGF) 2 did not overcome this deficiency. Furthermore, AIB1/SRC-3+/− and −/− mice showed similarly delayed healing of full-thickness excisional skin wounds, indicating that both alleles were required for proper tissue repair. Analysis of this defective wound healing showed reduced recruitment of inflammatory cells and macrophages, cytokine induction, and metalloprotease activity. Skin grafts from animals with different AIB1 genotypes and subsequent wounding of the grafts revealed that the defective healing was attributable to local factors and not to defective bone marrow responses. Indeed, wounds in AIB1+/− mice showed reduced expression of FGF10, FGFBP3, FGFR1, FGFR2b, and FGFR3, major local drivers of angiogenesis. We conclude that AIB1/SRC-3 modulates stromal cell responses via cross-talk with the FGF signaling pathway.
</description><dc:title>Role of the Nuclear Receptor Coactivator AIB1/SRC-3 in Angiogenesis and Wound Healing - Uncorrected Proof</dc:title><dc:creator>Maram Al-Otaiby, Elena Tassi, Marcel O. Schmidt, Chris D. Chien, Tabari Baker, Armando Ganoza Salas, Jianming Xu, Mary Furlong, Richard Schlegel, Anna T. Riegel, Anton Wellstein</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.032</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-15</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-15</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200034X/abstract?rss=yes"><title>S100P-Binding Protein, S100PBP, Mediates Adhesion through Regulation of Cathepsin Z in Pancreatic Cancer Cells - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200034X/abstract?rss=yes</link><description>
Several S100 proteins are up-regulated in pancreatic ductal adenocarcinoma (PDAC), the most significant being S100P. We previously reported on S100PBP, a binding partner of S100P, that shows no homology to any described protein and whose functions are completely unknown. To determine S100PBP expression across human tissues and organs, IHC was performed using both multiorgan- and in-house–constructed pancreatic TMAs. To establish S100PBP functions, cell lines with either stably overexpressed or silenced S100PBP were generated and investigated using Affymetrix gene expression arrays and complementary functional assays. We show that S100PBP is differentially expressed in various healthy and tumor specimens, which is both cancer- and tissue-type dependent. In healthy pancreas, S100PBP is expressed in the nuclear/perinuclear region of both exocrine and endocrine compartments. In early precancerous lesions, S100PBP is translocated to the cytoplasm, whereas in PDAC and metastatic lesions, its expression is significantly diminished. The most pronounced phenotypic change after manipulation of S100PBP expression was seen in adhesion; this was significantly reduced after S100PBP up-regulation and increased after S100PBP silencing. Up-regulation or silencing of S100PBP also led to a concomitant change in the levels of the protease cathepsin Z, the silencing of which significantly reduced PDAC cell adhesion. We further demonstrate that the interaction of cathepsin Z with arginine-glycine-aspartic acid–binding integrins, specifically αvβ5, mediates the changes seen in adhesion of PDAC cells.
</description><dc:title>S100P-Binding Protein, S100PBP, Mediates Adhesion through Regulation of Cathepsin Z in Pancreatic Cancer Cells - Uncorrected Proof</dc:title><dc:creator>Kate E. Lines, Claude Chelala, Branko Dmitrovic, Nilukshi Wijesuriya, Hemant M. Kocher, John F. Marshall, Tatjana Crnogorac-Jurcevic</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.031</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-13</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-13</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000375/abstract?rss=yes"><title>Identification of Three Novel Hearing Loss Mouse Strains with Mutations in the Tmc1 Gene - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000375/abstract?rss=yes</link><description>
We report the identification of three new mouse models, baringo, nice, and stitch, with recessively inherited sensorineural deafness due to novel mutations in the transmembrane channel-like gene 1 (Tmc1). These strains were generated by N-ethyl-N-nitrosourea mutagenesis. DNA sequence analysis revealed changes in c.545A&gt;G, c.1345T&gt;C, and c.1661G&gt;T, causing p.Y182C, p.Y449H, and p.W554L amino acid substitutions in baringo, nice, and stitch mutants, respectively. The mutations affect amino acid residues that are evolutionarily conserved across species. Similar to the previously reported Beethoven Tmc1 mutant, both p.Y182C and p.W554L are located outside a predicted transmembrane domain, whereas the p.Y449H mutation resides in the predicted transmembrane domain 4. Homozygous stitch-mutant mice have severe hearing loss at the age of 4 weeks and are deaf by the age of 8 weeks, whereas both baringo and nice mutants are profoundly deaf at the age of 4 weeks. None of the strains displays signs of vestibular dysfunction. Scanning electron microscopy revealed degeneration of outer hair cells in the basal region of baringo, nice, and stitch mutants. Immunolocalization studies revealed expression of TMC1 protein in the hair cells, spiral ganglion neurons, supporting cells, and stria ligament in the inner ear. Reduced levels of TMC1 protein were observed in the spiral ligament of mutants when compared with wild-type animals. These three allelic mutants provide valuable models for studying nonsyndromic recessive sensorineural hearing loss (DFNB7/11) in humans.
</description><dc:title>Identification of Three Novel Hearing Loss Mouse Strains with Mutations in the Tmc1 Gene - Uncorrected Proof</dc:title><dc:creator>Shehnaaz S.M. Manji, Kerry A. Miller, Louise H. Williams, Hans-Henrik M. Dahl</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.034</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-13</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-13</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000387/abstract?rss=yes"><title>DR3 Signaling Protects against Cisplatin Nephrotoxicity Mediated by Tumor Necrosis Factor - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000387/abstract?rss=yes</link><description>
The expression of death receptor 3 (DR3), a member of the tumor necrosis factor (TNF) receptor superfamily, is up-regulated in human tubular epithelial cells (TECs) during renal injury, but its function in this setting remains unknown. We used cisplatin to induce renal injury in wild-type (DR3+/+) or congenitally deficient DR3−/− mice to examine the in vivo role of DR3. Cisplatin induced the expression of DR3, its ligand, TNF-like ligand 1A (TL1A), and TNF in TECs, as observed in human renal injury. Cisplatin increased apoptotic death of DR3−/− TECs by twofold compared with DR3+/+ TECs, whereas it reduced the number of tubules expressing phospho-NF-κBp65Ser276 by 50% at 72 hours. Similar degrees of induction of DR3, TL1A, and TNF, and changes in apoptosis and phospho-NF-κBp65Ser276, were obtained in mouse kidney organ cultures treated with cisplatin for 3 hours, suggesting a direct effect on TECs. TNF was implicated in mediating cisplatin-induced tubular damage given that the in vivo co-administration of GM6001, an inhibitor of TNF maturation and release, significantly reduced TNF production and tubular damage. Moreover, TNF exacerbated, whereas TL1A reduced, cisplatin-induced apoptosis in the DR3+/+ mouse proximal tubule cell line, TKPTS. Our data demonstrate that cisplatin-induced nephrotoxicity is mitigated by DR3 signaling, suggesting that this occurs by antagonizing pro-apoptotic signals induced by TNF. Therefore, activating DR3 may be beneficial in reducing acute kidney injury.
</description><dc:title>DR3 Signaling Protects against Cisplatin Nephrotoxicity Mediated by Tumor Necrosis Factor - Uncorrected Proof</dc:title><dc:creator>Rafia S. Al-Lamki, WanHua Lu, Sarah Finlay, Jason P. Twohig, Eddie C.Y. Wang, Aviva M. Tolkovsky, John R. Bradley</dc:creator><dc:identifier>10.1016/j.ajpath.2012.01.003</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-13</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-13</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000430/abstract?rss=yes"><title>Full-Genome Dissection of an Epidemic of Severe Invasive Disease Caused by a Hypervirulent, Recently Emerged Clone of Group A Streptococcus - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000430/abstract?rss=yes</link><description>
An epidemic of severe invasive human infections caused by type emm59 group A Streptococcus (GAS), heretofore an exceedingly rare cause of disease, spread west to east across Canada over a 3-year period (2006 to 2008). GAS causes a myriad of diseases that range from pharyngitis to necrotizing fasciitis and toxic shock syndrome. By sequencing the genomes of 601 epidemic, historic, and other emm59 organisms, we discovered that a recently emerged, genetically distinct emm59 clone is responsible for the Canadian epidemic. Using near-real-time genome sequencing, we were able to show the spread of the Canadian epidemic clone into the United States. The extensive genome data permitted us to identify patterns of geographic dissemination as well as links between emm59 subclonal lineages that cause infections. Mouse and nonhuman primate models of infection demonstrated that the emerged clone is unusually virulent. Transmission of epidemic emm59 strains may have occurred primarily by skin contact, as suggested by an experimental model of skin transmission. In addition, the emm59 strains had a significantly impaired ability to persist in human saliva, colonized the oropharynx of mice, and seldom caused human pharyngitis. Our study contributes new information to the rapidly emerging field of molecular pathogenomics of bacterial epidemics and illustrates how full-genome data can be used to precisely illuminate the landscape of strain dissemination during a bacterial epidemic.
</description><dc:title>Full-Genome Dissection of an Epidemic of Severe Invasive Disease Caused by a Hypervirulent, Recently Emerged Clone of Group A Streptococcus - Uncorrected Proof</dc:title><dc:creator>Nahuel Fittipaldi, Stephen B. Beres, Randall J. Olsen, Vivek Kapur, Patrick R. Shea, M. Ebru Watkins, Concepcion C. Cantu, Daniel R. Laucirica, Leslie Jenkins, Anthony R. Flores, Marguerite Lovgren, Carmen Ardanuy, Josefina Liñares, Donald E. Low, Gregory J. Tyrrell, James M. Musser</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.037</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-13</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-13</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000193/abstract?rss=yes"><title>Dorsal Root Ganglia Damage in SIV-Infected Rhesus Macaques: An Animal Model of HIV-Induced Sensory Neuropathy - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000193/abstract?rss=yes</link><description>
HIV-associated sensory neuropathy (HIV-SN) is currently the most common neurological complication of chronic HIV infection and continues to substantially affect patient quality of life. Mechanisms underlying the neuronal damage and loss observed in sensory ganglia of HIV-infected individuals have not been sufficiently studied. The present study aimed to develop and characterize a model of HIV-SN using SIV-infected CD8 T-lymphocyte-depleted rhesus macaques (Macaca mulatta). Uninfected controls (n = 5), SIV-infected CD8-depleted (n = 4), and SIV-infected non-CD8-depleted (n = 6) animals were used. Of the six non-CD8-depleted animals, three were conventional progressors (progressing to AIDS &gt;1 year after infection) and three were rapid progressors (AIDS within 6 months). Dorsal root ganglia (DRG) were examined for histological hallmarks of HIV-SN, including satellitosis, presence of Nageotte nodules, and neuronophagia, as well as increased numbers of CD68+ macrophages and abundant viral replication. In contrast to non-CD8-depleted animals, which had mild to moderate DRG pathology, the CD8-depleted SIV-infected animals had moderate to severe DRG damage, with increased numbers of CD68+ satellite cells. Additionally, there was marked active viral replication in the affected DRG. These findings confirm that many features of HIV-SN can be recapitulated in the CD8-depleted SIV-infected rhesus macaque model within a short time frame and illustrate the importance of this model for study of sensory neuropathy.
</description><dc:title>Dorsal Root Ganglia Damage in SIV-Infected Rhesus Macaques: An Animal Model of HIV-Induced Sensory Neuropathy - Uncorrected Proof</dc:title><dc:creator>Tricia H. Burdo, Krystyna Orzechowski, Heather L. Knight, Andrew D. Miller, Kenneth Williams</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.016</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000211/abstract?rss=yes"><title>Altered Angiogenesis in Caveolin-1 Gene–Deficient Mice Is Restored by Ablation of Endothelial Nitric Oxide Synthase - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000211/abstract?rss=yes</link><description>
Caveolin-1 is an essential structural protein of caveolae, specialized plasma membrane organelles highly abundant in endothelial cells, where they regulate multiple functions including angiogenesis. Caveolin-1 exerts a tonic inhibition of endothelial nitric oxide synthase (eNOS) activity. Accordingly, caveolin-1 gene–disrupted mice have enhanced eNOS activity as well as increased systemic nitric oxide (NO) levels. We hypothesized that excess eNOS activity, secondary to caveolin deficiency, would mediate the decreased angiogenesis observed in caveolin-1 gene–disrupted mice. We tested tumor angiogenesis in mice lacking either one or both proteins, using in vitro, ex vivo, and in vivo assays. We show that endothelial cell migration, tube formation, cell sprouting from aortic rings, tumor growth, and angiogenesis are all significantly impaired in both caveolin-1–null and eNOS-null mice. We further show that these parameters were either partially or fully restored in double knockout mice that lack both caveolin-1 and eNOS. Furthermore, the effects of genetic ablation of eNOS are mimicked by the administration of the NOS inhibitor N-nitro-l-arginine methyl ester hydrochloride (L-NAME), including the reversal of the caveolin-1–null mouse angiogenic phenotype. This study is the first to demonstrate the detrimental effects of unregulated eNOS activity on angiogenesis, and shows that impaired tumor angiogenesis in caveolin-1–null mice is, at least in part, the result of enhanced eNOS activity.
</description><dc:title>Altered Angiogenesis in Caveolin-1 Gene–Deficient Mice Is Restored by Ablation of Endothelial Nitric Oxide Synthase - Uncorrected Proof</dc:title><dc:creator>Christudas Morais, Quteba Ebrahem, Bela Anand-Apte, Marie-Odile Parat</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.018</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000223/abstract?rss=yes"><title>Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular Dystrophy - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000223/abstract?rss=yes</link><description>
Merosin-deficient congenital muscular dystrophy type 1A (MDC1A) is a lethal muscle-wasting disease that is caused by mutations in the LAMA2 gene, resulting in the loss of laminin-α2 protein. MDC1A patients exhibit severe muscle weakness from birth, are confined to a wheelchair, require ventilator assistance, and have reduced life expectancy. There are currently no effective treatments or cures for MDC1A. Laminin-α2 is required for the formation of heterotrimeric laminin-211 (ie, α2, β1, and γ1) and laminin-221 (ie, α2, β2, and γ1), which are major constituents of skeletal muscle basal lamina. Laminin-111 (ie, α1, β1, and γ1) is the predominant laminin isoform in embryonic skeletal muscle and supports normal skeletal muscle development in laminin-α2–deficient muscle but is absent from adult skeletal muscle. In this study, we determined whether treatment with Engelbreth-Holm-Swarm–derived mouse laminin-111 protein could rescue MDC1A in the dyW−/− mouse model. We demonstrate that laminin-111 protein systemically delivered to the muscles of laminin-α2–deficient mice prevents muscle pathology, improves muscle strength, and dramatically increases life expectancy. Laminin-111 also prevented apoptosis in laminin-α2–deficient mouse muscle and primary human MDC1A myogenic cells, which indicates a conserved mechanism of action and cross-reactivity between species. Our results demonstrate that laminin-111 can serve as an effective protein substitution therapy for the treatment of muscular dystrophy in the dyW−/− mouse model and establish the potential for its use in the treatment of MDC1A.
</description><dc:title>Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular Dystrophy - Uncorrected Proof</dc:title><dc:creator>Jachinta E. Rooney, Jolie R. Knapp, Bradley L. Hodges, Ryan D. Wuebbles, Dean J. Burkin</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.019</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000235/abstract?rss=yes"><title>Overexpression of Tumor Necrosis Factor-α in the Lungs Alters Immune Response, Matrix Remodeling, and Repair and Maintenance Pathways - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000235/abstract?rss=yes</link><description>
Increased production of tumor necrosis factor (TNF)-α and matrix metalloproteinases (MMPs) is a feature of inflammatory lung diseases, including emphysema and fibrosis, but the divergent pathological characteristics that result indicate involvement of other processes in disease pathogenesis. Transgenic mice overexpressing TNF-α in type II alveolar epithelial cells under the control of the surfactant protein (SP)-C promoter develop pulmonary inflammation and emphysema but are resistant to induction of fibrosis by administration of bleomycin or transforming growth factor-β. To study the molecular mechanisms underlying the development of this phenotype, we used a microarray approach to characterize the pulmonary transcriptome of SP-C/TNF-α mice and wild-type littermates. Four-month-old SP-C/TNF-α mice displayed pronounced pulmonary inflammation, airspace enlargement, increased MMP-2 and MMP-9 levels, and altered expression of 2332 probes. The functional assessment of genes with increased expression revealed enrichment of inflammatory/immune responses and proteases, whereas genes involved in protease inhibition, angiogenesis, cross-linking of basement membrane proteins, and myofibroblast differentiation were predominantly decreased. Comparison with multiple lung disease models identified a set of genes unique to the SP-C/TNF-α model and revealed that lack of extracellular matrix production distinguished SP-C/TNF-α mice from fibrosis models. Activation of inflammatory and proteolytic pathways and disruption of maintenance and repair processes are central features of emphysema in this TNF-overexpression model. Impairment of myofibroblast differentiation and extracellular matrix production may underlie resistance to induction of fibrosis.
</description><dc:title>Overexpression of Tumor Necrosis Factor-α in the Lungs Alters Immune Response, Matrix Remodeling, and Repair and Maintenance Pathways - Uncorrected Proof</dc:title><dc:creator>Errol M. Thomson, Andrew Williams, Carole L. Yauk, Renaud Vincent</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.020</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000247/abstract?rss=yes"><title>Gene Deletions and Amplifications in Human Hepatocellular Carcinomas: Correlation with Hepatocyte Growth Regulation - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000247/abstract?rss=yes</link><description>
Tissues from 98 human hepatocellular carcinomas (HCCs) obtained from hepatic resections were subjected to somatic copy number variation (CNV) analysis. Most of these HCCs were discovered in livers resected for orthotopic transplantation, although in a few cases, the tumors themselves were the reason for the hepatectomies. Genomic analysis revealed deletions and amplifications in several genes, and clustering analysis based on CNV revealed five clusters. The LSP1 gene had the most cases with CNV (46 deletions and 5 amplifications). High frequencies of CNV were also seen in PTPRD (21/98), GNB1L (18/98), KIAA1217 (18/98), RP1-1777G6.2 (17/98), ETS1 (11/98), RSU1 (10/98), TBC1D22A (10/98), BAHCC1 (9/98), MAML2 (9/98), RAB1B (9/98), and YIF1A (9/98). The existing literature regarding hepatocytes or other cell types has connected many of these genes to regulation of cytoskeletal architecture, signaling cascades related to growth regulation, and transcription factors directly interacting with nuclear signaling complexes. Correlations with existing literature indicate that genomic lesions associated with HCC at the level of resolution of CNV occur on many genes associated directly or indirectly with signaling pathways operating in liver regeneration and hepatocyte growth regulation.
</description><dc:title>Gene Deletions and Amplifications in Human Hepatocellular Carcinomas: Correlation with Hepatocyte Growth Regulation - Uncorrected Proof</dc:title><dc:creator>Michael A. Nalesnik, George Tseng, Ying Ding, Guo-Sheng Xiang, Zhong-liang Zheng, YanPing Yu, James W. Marsh, George K. Michalopoulos, Jian-Hua Luo</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.021</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000259/abstract?rss=yes"><title>STAT3-Mediated Signaling Dysregulates Lung Fibroblast-Myofibroblast Activation and Differentiation in UIP/IPF - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000259/abstract?rss=yes</link><description>
STAT3 is a latent transcription factor that plays a role in regulating fibroblast function in fibrotic lung diseases. To further understand the role of STAT3 in the phenotypic divergence and function of human lung fibroblasts (LFs), we investigated the effect of basal and cytokine-induced STAT3 activity on indices of LF differentiation and activation, including expression of α-smooth muscle actin (α-SMA), collagen, and adhesion molecules Thy-1/CD90 and αv β3 and β5 integrins. We identified a population of fibroblasts from usual interstitial pneumonia (UIP)/idiopathic pulmonary fibrosis (IPF) lungs characterized by constitutively phosphorylated STAT3, lower proliferation rates, and diminished expression of α-SMA, Thy-1/CD90, and β3 integrins compared with control LFs. Staining of UIP lung biopsy specimens demonstrated that phosphorylated STAT3 was not present in α-SMA–positive fibroblastic foci but was observed in the nuclei of cells located in the areas of dense fibrosis. STAT3 activation in LFs did not significantly influence basal or transforming growth factor β1–induced collagen I expression but inhibited expression of α-SMA, Thy-1/CD90, and αv β3 integrins. Suppression of STAT3 signaling diminished resistance of IPF LFs to staurosporine-induced apoptosis and responsiveness to transforming growth factor β1 but increased basal α-SMA and restored β3 integrin expression in LFs via an ALK-5–dependent, SMAD3/7-independent mechanism. These data suggest that STAT3 activation regulates several pathways in human LFs associated with normal wound healing, whereas aberrant STAT3 signaling plays a critical role in UIP/IPF pathogenesis.
</description><dc:title>STAT3-Mediated Signaling Dysregulates Lung Fibroblast-Myofibroblast Activation and Differentiation in UIP/IPF - Uncorrected Proof</dc:title><dc:creator>Dmitri V. Pechkovsky, Cecilia M. Prêle, John Wong, Cory M. Hogaboam, Robin J. McAnulty, Geoffrey J. Laurent, Samuel S.-M. Zhang, Moisés Selman, Steven E. Mutsaers, Darryl A. Knight</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.022</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000260/abstract?rss=yes"><title>The Gne M712T Mouse as a Model for Human Glomerulopathy - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000260/abstract?rss=yes</link><description>
Pathological glomerular hyposialylation has been implicated in certain unexplained glomerulopathies, including minimal change nephrosis, membranous glomerulonephritis, and IgA nephropathy. We studied our previously established mouse model carrying a homozygous mutation in the key enzyme of sialic acid biosynthesis, N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Mutant mice died before postnatal day 3 (P3) from severe glomerulopathy with podocyte effacement and segmental glomerular basement membrane splitting due to hyposialylation. Administration of the sialic acid precursor N-acetylmannosamine (ManNAc) led to improved sialylation and survival of mutant pups beyond P3. We determined the onset of the glomerulopathy in the embryonic stage. A lectin panel, distinguishing normally sialylated from hyposialylated glycans, used WGA, SNA, PNA, Jacalin, HPA, and VVA, indicating glomerular hyposialylation of predominantly O-linked glycoproteins in mutant mice. The glomerular glycoproteins nephrin and podocalyxin were hyposialylated in this unique murine model. ManNAc treatment appeared to ameliorate the hyposialylation status of mutant mice, indicated by a lectin histochemistry pattern similar to that of wild-type mice, with improved sialylation of both nephrin and podocalyxin, as well as reduced albuminuria compared with untreated mutant mice. These findings suggest application of our lectin panel for categorizing human kidney specimens based on glomerular sialylation status. Moreover, the partial restoration of glomerular architecture in ManNAc-treated mice highlights ManNAc as a potential treatment for humans affected with disorders of glomerular hyposialylation.
</description><dc:title>The Gne M712T Mouse as a Model for Human Glomerulopathy - Uncorrected Proof</dc:title><dc:creator>Sravan Kakani, Tal Yardeni, Justin Poling, Carla Ciccone, Terren Niethamer, Enriko D. Klootwijk, Irini Manoli, Daniel Darvish, Shelley Hoogstraten-Miller, Patricia Zerfas, E. Tian, Kelly G. Ten Hagen, Jeffrey B. Kopp, William A. Gahl, Marjan Huizing</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.023</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000272/abstract?rss=yes"><title>Rapid Histamine-Induced Neutrophil Recruitment Is Sphingosine Kinase-1 Dependent - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000272/abstract?rss=yes</link><description>
Leukocyte recruitment to sites of inflammation is critical for the development of acute allergic responses. Rapid P-selectin up-regulation by endothelial cells is a key promoter of leukocyte infiltration in response to mediators such as histamine. However, the mechanisms underpinning this process are still incompletely understood. We examined the role of the sphingosine kinase/sphingosine-1-phosphate (SK/S1P) pathway and showed that in human umbilical vein endothelial cells, histamine rapidly activates SK in an extracellular signal-regulated kinase (ERK) 1/2-dependent manner, concurrent with the induction of P-selectin expression. Histamine activated both SK-1 and SK-2 isoforms; inhibition of SK-1, but not SK-2, attenuated histamine-induced P-selectin up-regulation and neutrophil rolling in vitro. S1P receptor antagonists failed to prevent histamine-induced P-selectin expression, and exogenous S1P did not increase P-selectin expression, suggesting that S1P cell surface receptors are not involved in this process. Finally, the role of both SK-1 and SK-2 in histamine-induced leukocyte rolling in vivo was assessed using pharmacological and genetic methods. Consistent with the in vitro findings, mice pretreated with either sphingosine kinase inhibitor or fingolimod (FTY720) significantly attenuated histamine-induced leukocyte rolling in the cremaster muscle. Similarly, Sphk1−/− but not Sphk2−/− mice exhibited reduced histamine-induced leukocyte rolling. These findings demonstrate a key role for SK-1 in histamine-induced rapid P-selectin up-regulation and associated leukocyte rolling, and suggest that endothelial SK-1 is an important contributor to allergic inflammation.
</description><dc:title>Rapid Histamine-Induced Neutrophil Recruitment Is Sphingosine Kinase-1 Dependent - Uncorrected Proof</dc:title><dc:creator>Wai Y. Sun, Latasha D. Abeynaike, Samantha Escarbe, Charles D. Smith, Stuart M. Pitson, Michael J. Hickey, Claudine S. Bonder</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.024</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000284/abstract?rss=yes"><title>Macrophage β2 Integrin–Mediated, HuR-Dependent Stabilization of Angiogenic Factor–Encoding mRNAs in Inflammatory Angiogenesis - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000284/abstract?rss=yes</link><description>
HuR is a member of the Drosophila Elav protein family that binds mRNA degradation sequences and prevents RNase-mediated degradation. Such HuR-mediated mRNA stabilization, which is stimulated by integrin engagement and is controlled at the level of HuR nuclear export, is critically involved in T-cell cytokine production. However, HuR's role in macrophage soluble factor production, in particular in response to angiogenic stimuli, has not yet been established. We show that the labile transcripts that encode vascular endothelial growth factor and matrix metalloproteinase-9 are stabilized when murine macrophages adhere to the β2 integrin ligand intercellular adhesion molecule-1. This mRNA stabilization response was absent in bone marrow–derived macrophages obtained from conditional macrophage-specific HuR knockout mice. The microvascular angiogenic response to an inflammatory stimulus (ie, subcutaneous polyvinyl alcohol sponge implantation) was markedly diminished in these macrophage HuR knockout mice despite the equal levels of macrophage localization to those observed in littermate wild-type controls. Furthermore, blood flow recovery and ischemic muscle neovascularization after femoral artery ligation were impaired in the conditional macrophage-specific HuR knockout mice. These results demonstrate that dynamic effects on mRNA, mediated by the RNA-binding and RNA-stabilizing protein HuR, are required for macrophage production of angiogenic factors, which play critical roles in the neovascular responses to a variety of stimuli, including tissue ischemia.
</description><dc:title>Macrophage β2 Integrin–Mediated, HuR-Dependent Stabilization of Angiogenic Factor–Encoding mRNAs in Inflammatory Angiogenesis - Uncorrected Proof</dc:title><dc:creator>Jiange Zhang, Yasha Modi, Timur Yarovinsky, Jun Yu, Mark Collinge, Themis Kyriakides, Yizhun Zhu, William C. Sessa, Ruggero Pardi, Jeffrey R. Bender</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.025</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000302/abstract?rss=yes"><title>TWEAK in Inclusion-Body Myositis Muscle - Possible Pathogenic Role of a Cytokine Inhibiting Myogenesis - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000302/abstract?rss=yes</link><description>
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 exert pleiotropic effects, including regulation of myogenesis. Sporadic inclusion-body myositis (IBM) is the most common muscle disease of the elderly population and leads to severe disability. IBM mesoangioblasts, different from mesoangioblasts in other inflammatory myopathies, display a myogenic differentiation defect. The objective of the present study was to investigate TWEAK-Fn14 expression in IBM and other inflammatory myopathies and explore whether TWEAK modulation affects myogenesis in IBM mesoangioblasts. TWEAK, Fn14, and NF-κB expression was assessed by immunohistochemistry and Western blot in cell samples from both muscle biopsies and primary cultures. Mesoangioblasts isolated from samples of IBM, dermatomyositis, polymyositis, and control muscles were treated with recombinant human TWEAK, Fn14-Fc chimera, and anti-TWEAK antibody. TWEAK-RNA interference was performed in IBM and dermatomyositis mesoangioblasts. TWEAK levels in culture media were determined by enzyme-linked immunosorbent assay. In IBM muscle, we found increased TWEAK-Fn14 expression. Increased levels of TWEAK were found in differentiation medium from IBM mesoangioblasts. Moreover, TWEAK inhibited myogenic differentiation of mesoangioblasts. Consistent with this evidence, TWEAK inhibition by Fn14-Fc chimera or short interfering RNA induced myogenic differentiation of IBM mesoangioblasts. We provide evidence that TWEAK is a negative regulator of human mesoangioblast differentiation. Dysregulation of the TWEAK-Fn14 axis in IBM muscle may induce progressive muscle atrophy and reduce activation and differentiation of muscle precursor cells.
</description><dc:title>TWEAK in Inclusion-Body Myositis Muscle - Possible Pathogenic Role of a Cytokine Inhibiting Myogenesis - Uncorrected Proof</dc:title><dc:creator>Roberta Morosetti, Carla Gliubizzi, Cristina Sancricca, Aldobrando Broccolini, Teresa Gidaro, Matteo Lucchini, Massimiliano Mirabella</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.027</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000314/abstract?rss=yes"><title>Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000314/abstract?rss=yes</link><description>
Pancreatic cancer is a significant cause of cancer mortality worldwide as the disease has advanced significantly in patients before symptoms are evident. The signal transduction pathways that promote this rapid progression are not well understood. Ack1 or TNK2, an ubiquitously expressed oncogenic non–receptor tyrosine kinase, integrates signals from ligand-activated receptor tyrosine kinases to modulate intracellular signaling cascades. In the present study, we investigated the Ack1 activation profile in a pancreatic cancer tumor microarray, and observed that expression levels of activated Ack1 and pTyr284-Ack1 positively correlated with the severity of disease progression and inversely correlated with the survival of patients with pancreatic cancer. To explore the mechanisms by which Ack1 promotes tumor progression, we investigated the role of AKT/PKB, an oncogene and Ack1-interacting protein. Ack1 activates AKT directly in pancreatic and other cancer cell lines by phosphorylating AKT at Tyr176 to promote cell survival. In addition, the Ack1 inhibitor AIM-100 not only inhibited Ack1 activation but also suppressed AKT tyrosine phosphorylation, leading to cell cycle arrest in the G1 phase. This effect resulted in a significant decrease in the proliferation of pancreatic cancer cells and induction of apoptosis. Collectively, our data indicate that activated Ack1 could be a prognostic marker for ascertaining early or advanced pancreatic cancer. Thus, Ack1 inhibitors hold promise for therapeutic intervention to inhibit pancreatic tumor growth.
</description><dc:title>Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression - Uncorrected Proof</dc:title><dc:creator>Kiran Mahajan, Domenico Coppola, Y. Ann Chen, Weiwei Zhu, Harshani R. Lawrence, Nicholas J. Lawrence, Nupam P. Mahajan</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.028</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000326/abstract?rss=yes"><title>Atomic Identification of Fluorescent Q-Dots on Tau-Positive Fibrils in 3D-Reconstructed Pick Bodies - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000326/abstract?rss=yes</link><description>
Pick body disease, characterized by the presence of Pick bodies, is distinguished from neurofibrillary tangles in Alzheimer disease on the basis of their smooth, spherical shape. Quantum dots (QDs) are nanometer-scale, water-soluble fluorophores that are detectable both as a fluorescent signal by light microscopy and as electron-dense particles under electron microscopy. In this study, tau-positive Pick bodies were immunofluorescently labeled with QD nanocrystals composed of cadmium selenide for three-dimensional (3D) reconstruction and subsequently subjected to electron microscopic observation to identify QD immunolabeling on the same Pick body for comparison in detail. The identity of the QD nanocrystals, which label the tau-positive fibrils, was confirmed by the presence of both cadmium and selenium on these nanocrystals, demonstrated as parallel peaks corresponding to these atoms on energy-dispersive X-ray spot analysis under super-resolution scanning transmission electron microscopy. This confirmation of the specificity of the QD labeling through both its fluorescence and energy-dispersive X-ray spectra reinforces the reliability of the labeling. In addition, this exact comparison of the same structure by electron microscopy and 3D light microscopy demonstrates how its ultrastructural details are related to its surrounding structures on a 3D basis, providing further insights into how molecules woven into specific pathological ultrastructures are at work in situ.
</description><dc:title>Atomic Identification of Fluorescent Q-Dots on Tau-Positive Fibrils in 3D-Reconstructed Pick Bodies - Uncorrected Proof</dc:title><dc:creator>Miho Uematsu, Eijiro Adachi, Ayako Nakamura, Kuniaki Tsuchiya, Toshiki Uchihara</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.029</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000338/abstract?rss=yes"><title>Pleiotropic Action of Renal Cell Carcinoma-Dysregulated miRNAs on Hypoxia-Related Signaling Pathways - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000338/abstract?rss=yes</link><description>
The von Hippel-Lindau (VHL) gene is lost in ∼70% of all renal cell carcinomas (RCCs); however, increasing evidence supports the involvement of alternative mechanisms in the regulation of VHL expression, including suppression by microRNAs (miRNAs). miRNAs are small, noncoding RNA molecules that regulate gene expression through binding to target mRNAs. In this study, we found that miRNAs, which are dysregulated in cases of RCC, can target multiple members of RCC-related signaling pathways. Importantly, both VHL and the hypoxia-inducible factor 1-α gene are experimentally validated and are likely direct targets of miR-17-5p and miR-224, as shown by both luciferase assay and Western blot analysis. We found a negative correlation between miR-17-5p and its two predicted targets, VEGF-A and EGLN3, and between miR-224 and its targets SMAD4 and SMAD5 in RCC specimens, suggesting that downstream signaling pathways are also modulated by clear cell RCC-dysregulated miRs. Results from our bioinformatics analysis show that a single miRNA molecule can target multiple components of the same pathway and that multiple miRNAs can target the same molecule. Our results also indicate that miRNAs represent a mechanism for the inactivation of VHL in cases of RCC and can elucidate a new dimension in cancer pathogenesis. As such, miRNAs exemplify new potential therapeutic targets with a significant effect on both tumor growth and metastatic potential.
</description><dc:title>Pleiotropic Action of Renal Cell Carcinoma-Dysregulated miRNAs on Hypoxia-Related Signaling Pathways - Uncorrected Proof</dc:title><dc:creator>Zsuzsanna Lichner, Salvador Mejia-Guerrero, Monika Ignacak, Adriana Krizova, Tian Tian Bao, Andrew Hany Fathy Girgis, Youssef Maged Youssef, George Makram Yousef</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.030</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000399/abstract?rss=yes"><title>A Defect of the INK4-Cdk4 Checkpoint and Myc Collaborate in Blastoid Mantle Cell Lymphoma–Like Lymphoma Formation in Mice - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000399/abstract?rss=yes</link><description>
Mantle cell lymphoma (MCL) is a B-cell malignancy characterized by a monoclonal proliferation of lymphocytes with the co-expression of CD5 and CD43, but not of CD23. Typical MCL is associated with overexpression of cyclin D1, and blastoid MCL variants are associated with Myc (alias c-myc) translocations. In this study, we developed a murine model of MCL-like lymphoma by crossing Cdk4R24C mice with Myc-3′RR transgenic mice. The Cdk4R24C mouse is a knockin strain that expresses a Cdk4 protein that is resistant to inhibition by p16INK4a as well as other INK4 family members. Ablation of INK4 control on Cdk4 does not affect lymphomagenesis, B-cell maturation, and functions in Cdk4R24C mice. Additionally, B cells were normal in numbers, cell cycle activity, mitogen responsiveness, and Ig synthesis in response to activation. By contrast, breeding Cdk4R24C mice with Myc-3′RR transgenic mice prone to develop aggressive Burkitt lymphoma–like lymphoma (CD19+IgM+IgD+ cells) leads to the development of clonal blastoid MCL-like lymphoma (CD19+IgM+CD5+CD43+CD23− cells) in Myc/Cdk4R24C mice. Western blot analysis revealed high amounts of Cdk4/cyclin D1 complexes as the main hallmark of these lymphomas. These results indicate that although silent in nonmalignant B cells, a defect in the INK4-Cdk4 checkpoint can participate in lymphomagenesis in conjunction with additional alterations of cell cycle control, a situation that might be reminiscent of the development of human blastoid MCL.
</description><dc:title>A Defect of the INK4-Cdk4 Checkpoint and Myc Collaborate in Blastoid Mantle Cell Lymphoma–Like Lymphoma Formation in Mice - Uncorrected Proof</dc:title><dc:creator>Christelle Vincent-Fabert, Rémi Fiancette, Pauline Rouaud, Christel Baudet, Véronique Truffinet, Virginie Magnone, Angélique Guillaudeau, Michel Cogné, Pierre Dubus, Yves Denizot</dc:creator><dc:identifier>10.1016/j.ajpath.2012.01.004</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000405/abstract?rss=yes"><title>Partial Loss of Epithelial Phenotype in Kindlin-1–Deficient Keratinocytes - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000405/abstract?rss=yes</link><description>
Kindlin-1 is an adaptor protein that is expressed by most epithelial cells and has been implicated in integrin bidirectional signaling. Mutations in the gene encoding kindlin-1 are associated with Kindler syndrome, a recessively inherited disorder that is characterized by fragile skin. Functionally, a loss of kindlin-1 impairs the adhesion of basal keratinocytes to the extracellular matrix both in vivo and in vitro. In this study, we show that the phenotype of mutant keratinocytes deficient in kindlin-1 is characterized by the modification of the cortical actin network and increased plasticity of the plasma membrane. At the molecular level, expression of several proteins associated with an epithelial phenotype, such as α6β4 integrin, collagen XVII, E-cadherin, and desmoglein-3, is strongly reduced, whereas, surprisingly, laminin 332 is synthesized in larger amounts than in control keratinocytes. In contrast, mesenchymal markers such as vimentin and fibronectin are increased in keratinocytes lacking kindlin-1. The switch in cell plasticity and protein expression was confirmed by siRNA-mediated down-regulation of kindlin-1 in HaCaT epithelial cells. Furthermore, there was up-regulation of matrix metalloproteinases and pro-inflammatory cytokines in kindlin-1–deficient keratinocytes. These results provide new insights into the pathogenic mechanisms that take place in Kindler syndrome. Moreover, the constellation of molecular defects associated with the loss of kindlin-1 may explain the higher incidence of skin cancer observed in patients affected with this disorder.
</description><dc:title>Partial Loss of Epithelial Phenotype in Kindlin-1–Deficient Keratinocytes - Uncorrected Proof</dc:title><dc:creator>Haiyan Qu, Tingting Wen, Monika Pesch, Monique Aumailley</dc:creator><dc:identifier>10.1016/j.ajpath.2012.01.005</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000417/abstract?rss=yes"><title>Transforming Growth Factor Beta-Induced (TGFBI) Is an Anti-Adhesive Protein Regulating the Invasive Growth of Melanoma Cells - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000417/abstract?rss=yes</link><description>
Melanoma is a malignancy characterized by high invasive/metastatic potential, with no efficient therapy after metastasis. Understanding the molecular mechanisms underlying the invasive/metastatic tendency is therefore important. Our genome-wide gene expression analyses revealed that human melanoma cell lines WM793 and especially WM239 (vertical growth phase and metastatic cells, respectively) overexpress the extracellular matrix (ECM) protein transforming growth factor β induced (TGFBI). In adhesion assays, recombinant TGFBI was strongly anti-adhesive for both melanoma cells and skin fibroblasts. TGFBI further impaired the adhesion of melanoma cells to the adhesive ECM proteins fibronectin, collagen-I, and laminin, known to interact with it. Unexpectedly, WM239 cells migrated/invaded more effectively in three-dimensional collagen-I and Matrigel cultures after knockdown of TGFBI by shRNA expression. However, in the physiological subcutaneous microenvironment in nude mice, after TGFBI knockdown, these cells showed markedly impaired tumor growth and invasive capability; the initially formed small tumors later underwent myxoid degeneration and completely regressed. By contrast, the expanding control tumors showed intense TGFBI staining at the tumor edges, co-localizing with the fibrillar fibronectin/tenascin-C/periostin structures that characteristically surround melanoma cells at invasion fronts. Furthermore, TGFBI was found in similar fibrillar structures in clinical human melanoma metastases as well, co-localizing with fibronectin. These data imply an important role for TGFBI in the ECM deposition and invasive growth of melanoma cells, rendering TGFBI a potential target for therapeutic interventions.
</description><dc:title>Transforming Growth Factor Beta-Induced (TGFBI) Is an Anti-Adhesive Protein Regulating the Invasive Growth of Melanoma Cells - Uncorrected Proof</dc:title><dc:creator>Pirjo Nummela, Johanna Lammi, Johanna Soikkeli, Olli Saksela, Pirjo Laakkonen, Erkki Hölttä</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.035</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000429/abstract?rss=yes"><title>Intestinal Mast Cell Levels Control Severity of Oral Antigen-Induced Anaphylaxis in Mice - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000429/abstract?rss=yes</link><description>
Food-triggered anaphylaxis can encompass a variety of symptoms that affect multiple organ systems and can be life threatening. The molecular distinction between non–life-threatening and life-threatening modes of such anaphylaxis has not yet been delineated. In this study, we sought to identify the specific immune functions that regulate the severity of oral antigen-induced anaphylaxis. We thus developed an experimental mouse model in which repeated oral challenge of ovalbumin-primed mice induced an FcεRI and IgE-dependent oral antigen-triggered anaphylaxis that involved multiple organ systems. Strikingly, the severity of the systemic symptoms of anaphylaxis (eg, hypothermia) positively correlated with the levels of intestinal mast cells (r = −0.53; P &lt; 0.009). In addition, transgenic mice with both increased intestinal and normal systemic levels of mast cells showed increased severity of both intestinal and extra-intestinal symptoms of IgE-mediated passive as well as oral antigen and IgE-triggered anaphylaxis. In conclusion, these observations indicate that the density of intestinal mast cells controls the severity of oral antigen-induced anaphylaxis. Thus, an awareness of intestinal mast cell levels in patients with food allergies may aid in determining their susceptibility to life-threatening anaphylaxis and may eventually aid in the treatment of food-triggered anaphylaxis.
</description><dc:title>Intestinal Mast Cell Levels Control Severity of Oral Antigen-Induced Anaphylaxis in Mice - Uncorrected Proof</dc:title><dc:creator>Richard Ahrens, Heather Osterfeld, David Wu, Chun-Yu Chen, Muthuvel Arumugam, Katherine Groschwitz, Richard Strait, Yui-hsi Wang, Fred D. Finkelman, Simon P. Hogan</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.036</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000156/abstract?rss=yes"><title>Nitric Oxide–Releasing Nanoparticles Accelerate Wound Healing by Promoting Fibroblast Migration and Collagen Deposition - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000156/abstract?rss=yes</link><description>
Wound healing is a complex process that involves coordinated interactions between diverse immunological and biological systems. Long-term wounds remain a challenging clinical problem, affecting approximately 6 million patients per year, with a high economic impact. To exacerbate the problem, these wounds render the individual susceptible to life-threatening microbial infections. Because current therapeutic strategies have proved suboptimal, it is imperative to focus on new therapeutic approaches and the development of technologies for both short- and long-term wound management. In recent years, nitric oxide (NO) has emerged as a critical molecule in wound healing, with NO levels increasing rapidly after skin damage and gradually decreasing as the healing process progresses. In this study, we examined the effects of a novel NO-releasing nanoparticle technology on wound healing in mice. The results show that the NO nanoparticles (NO-np) significantly accelerated wound healing. NO-np modified leukocyte migration and increased tumor growth factor-β production in the wound area, which subsequently promoted angiogenesis to enhance the healing process. By using human dermal fibroblasts, we demonstrate that NO-np increased fibroblast migration and collagen deposition in wounded tissue. Together, these data show that NO-releasing nanoparticles have the ability to modulate and accelerate wound healing in a pleiotropic manner.
</description><dc:title>Nitric Oxide–Releasing Nanoparticles Accelerate Wound Healing by Promoting Fibroblast Migration and Collagen Deposition - Uncorrected Proof</dc:title><dc:creator>George Han, Long N. Nguyen, Chitralekha Macherla, Joel M. Friedman, Joshua D. Nosanchuk, Luis R. Martinez</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.013</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-06</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-06</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200017X/abstract?rss=yes"><title>Aberrant Stratifin Overexpression Is Regulated by Tumor-Associated CpG Demethylation in Lung Adenocarcinoma - Corrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200017X/abstract?rss=yes</link><description>
We previously have shown the aberrant overexpression of stratifin (SFN, 14-3-3 ς) in lung adenocarcinoma. Although SFN is known to facilitate tumor cell proliferation, the mechanism that underlies its aberrant expression has remained unclear. SFN, the downstream target of p53, often has been reported to be hypermethylated and subsequently silenced in certain cancers; however, its hypomethylation-linked reactivation has not yet been validated. In this study, we investigated the DNA methylation status of the SFN promoter region using 8 lung cancer cell lines and 32 specimens of adenocarcinoma tissue. Real-time methylation-specific PCR analysis showed that although both normal lung tissue and adenocarcinoma in situ bore a completely methylated SFN promoter, the promoter region in almost all invasive adenocarcinomas was at least partially methylated. The expression of SFN and its level of methylation were correlated strongly. Furthermore, statistical analysis revealed that the level of methylation became reduced with progression of the pathologic stage, although no clear relationship between methylation level and p53 abnormality was found. These results suggest that methylation-related silencing of SFN occurs in both normal lung tissues and adenocarcinoma in situ, and that demethylation of the SFN promoter participates in the aberrant expression of SFN in invasive adenocarcinoma cells, independently of p53 alteration. This novel finding might be informative for clarifying the mechanism that underlies the progression of early lung adenocarcinoma.
</description><dc:title>Aberrant Stratifin Overexpression Is Regulated by Tumor-Associated CpG Demethylation in Lung Adenocarcinoma - Corrected Proof</dc:title><dc:creator>Aya Shiba-Ishii, Masayuki Noguchi</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.014</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-06</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-06</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000296/abstract?rss=yes"><title>ProxTom Lymphatic Vessel Reporter Mice Reveal Prox1 Expression in the Adrenal Medulla, Megakaryocytes, and Platelets - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000296/abstract?rss=yes</link><description>
Lymphatic vessels (LVs) are important structures for antigen presentation, for lipid metabolism, and as conduits for tumor metastases, but they have been difficult to visualize in vivo. Prox1 is a transcription factor that is necessary for lymphangiogenesis in ontogeny and the maintenance of LVs. To visualize LVs in the lymph node of a living mouse in real time, we made the ProxTom transgenic mouse in a C57BL/6 background using red fluorescent LVs that are suitable for in vivo imaging. The ProxTom transgene contained all Prox1 regulatory sequences and was faithfully expressed in LVs coincident with endogenous Prox1 expression. The progenies of a ProxTom × Hec6stGFP cross were imaged using two-photon laser scanning microscopy, allowing the simultaneous visualization of LVs and high endothelial venules in a lymph node of a living mouse for the first time. We confirmed the expression of Prox1 in the adult liver, lens, and dentate gyrus. These intensely fluorescent mice revealed the expression of Prox1 in three novel sites: the neuroendocrine cells of the adrenal medulla, megakaryocytes, and platelets. The novel sites identified herein suggest previously unknown roles for Prox. The faithful expression of the fluorescent reporter in ProxTom LVs indicates that these mice have potential utility in the study of diseases as diverse as lymphedema, filariasis, transplant rejection, obesity, and tumor metastasis.
</description><dc:title>ProxTom Lymphatic Vessel Reporter Mice Reveal Prox1 Expression in the Adrenal Medulla, Megakaryocytes, and Platelets - Uncorrected Proof</dc:title><dc:creator>Lucy A. Truman, Kevin L. Bentley, Elenoe C. Smith, Stephanie A. Massaro, David G. Gonzalez, Ann M. Haberman, Myriam Hill, Dennis Jones, Wang Min, Diane S. Krause, Nancy H. Ruddle</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.026</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-06</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-06</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000181/abstract?rss=yes"><title>Amyloid Precursor Protein Is a Biomarker for Transformed Human Pluripotent Stem Cells - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000181/abstract?rss=yes</link><description>
Increasing evidence suggests an important function of the β-amyloid precursor protein (APP) in malignant disease in humans; however, the biological basis for this evidence is not well understood at present. To understand the role of APP in transformed pluripotent stem cells, we studied its expression levels in human testicular germ cell tumors using patient tissues, model cell lines, and an established xenograft mouse model. In the present study, we demonstrate the cooperative expression of APP with prominent pluripotency-related genes such as Sox2, NANOG, and POU5F1 (Oct3/4). The closest homologue family member, APLP2, showed no correlation to these stem cell factors. In addition, treatment with histone deacetylase (HDAC) inhibitors suppressed the levels of APP and stem cell markers. Loss of pluripotency, either spontaneously or as a consequence of treatment with an HDAC inhibitor, was accompanied by decreased APP protein levels both in vitro and in vivo. These observations suggest that APP represents a novel and specific biomarker in human transformed pluripotent stem cells that can be selectively modulated by HDAC inhibitors.
</description><dc:title>Amyloid Precursor Protein Is a Biomarker for Transformed Human Pluripotent Stem Cells - Uncorrected Proof</dc:title><dc:creator>Vivek Venkataramani, Knut Thiele, Carl Ludwig Behnes, Gerald G. Wulf, Paul Thelen, Lennart Opitz, Gabriella Salinas-Riester, Oliver Wirths, Thomas A. Bayer, Stefan Schweyer</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.015</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-03</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-03</prism:publicationDate><prism:section>REGULAR ARTICLE</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200020X/abstract?rss=yes"><title>Negative Feedback Mechanisms Surpass the Effect of Intrinsic EGFR Activation during Skin Chemical Carcinogenesis - Uncorrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS000294401200020X/abstract?rss=yes</link><description>
The negative feedback regulation of epidermal growth factor receptor (EGFR) and other tyrosine kinase receptors, including receptor dephosphorylation and endocytosis followed by degradation, is becoming recognized as a major determinant of receptor function. To evaluate the significance of the negative regulation of EGFR during carcinogenesis in vivo, we subjected the mutant mouse line Dsk5, in which the intrinsic activation of the receptor due to a point mutation is normally counterbalanced by increased posttranslational receptor down-regulation, to skin chemical carcinogenesis. Dsk5 mice showed reduced tumor numbers and tumor burden compared with control littermates, and Dsk5-derived tumors showed a reduction in the activation and total levels of EGFR. Furthermore, the transcript levels of several molecules known to act as negative regulators of EGFR were significantly increased in Dsk5-derived tumors. Another intriguing observation was the appearance of tumors with sebaceous differentiation in the ears of Dsk5 mice after chemical carcinogenesis. Further studies are necessary to reveal whether these tumors represent a cell type–specific evasion from EGFR negative feedback machinery. In conclusion, this study reveals that several negative feedback regulators contribute to suppression of the intrinsic activation of mutant EGFR during skin carcinogenesis, stressing the potential exploitation of negative regulators as either therapeutic targets or diagnostic tools in cancer and other diseases.
</description><dc:title>Negative Feedback Mechanisms Surpass the Effect of Intrinsic EGFR Activation during Skin Chemical Carcinogenesis - Uncorrected Proof</dc:title><dc:creator>Maik Dahlhoff, Christian Rose, Martin Hrabé de Angelis, Eckhard Wolf, Marlon R. Schneider</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.017</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-02-02</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-02-02</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000132/abstract?rss=yes"><title>Chemotherapy-Associated Angiogenesis in Neuroblastoma Tumors - Corrected Proof</title><link>http://www.journals.elsevierhealth.com/periodicals/ajpa/article/PIIS0002944012000132/abstract?rss=yes</link><description>
The influences of cytotoxic drugs on endothelial cells remain incompletely understood. Herein, we examined the effects of chemotherapeutic agents in experimental angiogenesis models and analyzed vessel densities in clinical neuroblastoma tumor samples. Cisplatin (20 to 500 ng/mL), doxorubicin (4 to 100 ng/mL), and vincristine (0.5 to 4 ng/mL), drugs commonly involved in neuroblastoma therapy protocols, induced pro-angiogenic effects in different angiogenesis models. They enhanced endothelial cell tube formation, endothelial cell sprouting from spheroids, formation of tip cells in the sprouting assay, expression of αvβ3 integrin, and vitronectin binding. All three drugs increased global cellular kinase phosphorylation levels, including the angiogenesis-relevant molecules protein kinase Cβ and Akt. Pharmacological inhibition of protein kinase Cβ or Akt upstream of phosphatidylinositol 3-kinase reduced chemotherapy-induced endothelial cell tube formation. Moreover, the investigated chemotherapeutics dose dependently induced vessel formation in the chick chorioallantoic membrane assay. Tumor samples from seven high-risk patients with neuroblastoma were analyzed for vessel density by IHC. Results revealed that neuroblastoma samples taken after chemotherapy consistently showed an enhanced microvessel density compared with the corresponding samples taken before chemotherapy. In conclusion, our data show that chemotherapy can activate endothelial cells by inducing multiple pro-angiogenic signaling pathways and exert pro-angiogenic effects in vitro and in vivo. Moreover, we report a previously unrecognized clinical phenomenon that might, in part, be explained by our experimental observations: chemotherapy-associated enhanced vessel formation in tumors from patients with neuroblastoma.
</description><dc:title>Chemotherapy-Associated Angiogenesis in Neuroblastoma Tumors - Corrected Proof</dc:title><dc:creator>Martin Michaelis, Nora Hinsch, U. Ruth Michaelis, Florian Rothweiler, Thorsten Simon, Hans W. ilhelm Doerr, Jaroslav Cinatl, Jindrich Cinatl</dc:creator><dc:identifier>10.1016/j.ajpath.2011.12.011</dc:identifier><dc:source>The American Journal of Pathology (2012)</dc:source><dc:date>2012-01-30</dc:date><prism:publicationName>The American Journal of Pathology</prism:publicationName><prism:publicationDate>2012-01-30</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item></rdf:RDF>
